These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 9864741)
1. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Liau LM; Fakhrai H; Black KL Neurol Res; 1998 Dec; 20(8):742-7. PubMed ID: 9864741 [TBL] [Abstract][Full Text] [Related]
2. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Fakhrai H; Dorigo O; Shawler DL; Lin H; Mercola D; Black KL; Royston I; Sobol RE Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2909-14. PubMed ID: 8610141 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of antisense epidermal growth factor receptor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo. Pu P; Liu X; Liu A; Cui J; Zhang Y J Neurosurg; 2000 Jan; 92(1):132-9. PubMed ID: 10616092 [TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effect of EGFR antisense cDNA on rat C6 gliomas in vivo]. Liu X; Pu P; Wang G Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):422-4. PubMed ID: 10920933 [TBL] [Abstract][Full Text] [Related]
5. Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. Tseng SH; Hwang LH; Lin SM J Immunother; 1997 Sep; 20(5):334-42. PubMed ID: 9336740 [TBL] [Abstract][Full Text] [Related]
6. Antisense TGF-beta2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Maggard M; Meng L; Ke B; Allen R; Devgan L; Imagawa DK Ann Surg Oncol; 2001; 8(1):32-7. PubMed ID: 11206222 [TBL] [Abstract][Full Text] [Related]
7. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. Saleh M; Wiegmans A; Malone Q; Stylli SS; Kaye AH J Natl Cancer Inst; 1999 Mar; 91(5):438-45. PubMed ID: 10070943 [TBL] [Abstract][Full Text] [Related]
8. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Trojan J; Johnson TR; Rudin SD; Ilan J; Tykocinski ML; Ilan J Science; 1993 Jan; 259(5091):94-7. PubMed ID: 8418502 [TBL] [Abstract][Full Text] [Related]
9. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464 [TBL] [Abstract][Full Text] [Related]
10. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats. Zhu X; Lu C; Xiao B; Qiao J; Sun Y J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102 [TBL] [Abstract][Full Text] [Related]
11. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. Liu Y; Wang Q; Kleinschmidt-DeMasters BK; Franzusoff A; Ng KY; Lillehei KO J Neurooncol; 2007 Jan; 81(2):149-62. PubMed ID: 16941073 [TBL] [Abstract][Full Text] [Related]
12. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Sasaki M; Wizigmann-Voos S; Risau W; Plate KH Int J Dev Neurosci; 1999; 17(5-6):579-91. PubMed ID: 10571419 [TBL] [Abstract][Full Text] [Related]
13. Pro-inflammatory modification of cancer cells microsurroundings increases the survival rates for rats with low differentiated malignant glioma of brain. Zaitsev S; Sharma HS; Sharma A; Manzhulo I; Polevshchikov A; Kudriavtsev I; Khotimchenko Y; Pak O; Bryukhovetskiy A; Bryukhovetskiy I Int Rev Neurobiol; 2020; 151():253-279. PubMed ID: 32448611 [TBL] [Abstract][Full Text] [Related]
14. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Ständer M; Naumann U; Dumitrescu L; Heneka M; Löschmann P; Gulbins E; Dichgans J; Weller M Gene Ther; 1998 Sep; 5(9):1187-94. PubMed ID: 9930319 [TBL] [Abstract][Full Text] [Related]
15. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Parsa AT; Chakrabarti I; Hurley PT; Chi JH; Hall JS; Kaiser MG; Bruce JN Neurosurgery; 2000 Oct; 47(4):993-9; discussion 999-1000. PubMed ID: 11014444 [TBL] [Abstract][Full Text] [Related]
16. [Connexin 43 gene in the in vivo treatment of cerebral glioma in C6 rats]. Xia Z; Pu P; Huang Q; Zhang Y; Jiang Y; You Y Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):212-4. PubMed ID: 12515608 [TBL] [Abstract][Full Text] [Related]
17. The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo. Pu P; Kang C; Li J; Jiang H; Cheng J J Neurooncol; 2006 Jan; 76(1):1-11. PubMed ID: 16402276 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Machein MR; Risau W; Plate KH Hum Gene Ther; 1999 May; 10(7):1117-28. PubMed ID: 10340544 [TBL] [Abstract][Full Text] [Related]
19. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. Yang SY; Liu H; Zhang JN DNA Cell Biol; 2004 Jun; 23(6):381-9. PubMed ID: 15231071 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Saleh M; Stacker SA; Wilks AF Cancer Res; 1996 Jan; 56(2):393-401. PubMed ID: 8542597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]